Cargando…
Development of erythropoietin receptor-targeted drug delivery system against breast cancer using tamoxifen-loaded nanostructured lipid carriers
Tamoxifen (TAM) has been used in the treatment of breast cancers and is supplemented with erythropoietin (EPO) to alleviate the cancer-related anemia. The purported deleterious effects caused by the use of EPO with chemotherapeutic agents in the treatment of cancer-related anemia vary across studies...
Autores principales: | Beh, Chaw Yee, How, Chee Wun, Foo, Jhi Biau, Foong, Jia Ning, Selvarajah, Gayathri Thevi, Rasedee, Abdullah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358988/ https://www.ncbi.nlm.nih.gov/pubmed/28352153 http://dx.doi.org/10.2147/DDDT.S123939 |
Ejemplares similares
-
Enhanced anti-mammary gland cancer activities of tamoxifen-loaded erythropoietin-coated drug delivery system
por: Beh, Chaw Yee, et al.
Publicado: (2019) -
Zerumbone-Loaded Nanostructured Lipid Carrier Induces Apoptosis of Canine Mammary Adenocarcinoma Cells
por: Foong, Jia Ning, et al.
Publicado: (2018) -
Effect of fetal bovine serum on erythropoietin receptor expression and viability of breast cancer cells
por: Teo, Guan-Young, et al.
Publicado: (2020) -
Zerumbone-loaded nanostructured lipid carriers: preparation, characterization, and antileukemic effect
por: Rahman, Heshu Sulaiman, et al.
Publicado: (2013) -
Recombinant human Erythropoietin enhanced the cytotoxic effects of tamoxifen toward the spheroid MCF-7 breast cancer cells
por: Shujaa Edin, Hareth Y., et al.
Publicado: (2021)